drugset / Trial / NCT07131644

Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

NCT07131644

Phase 2 Not yet recruiting 120 enrolled West China Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.

Timeline

Start
2025-09-13
Primary completion
2027-09-01
Completion
2028-02-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule